Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mortarini, R.
Right arrow Articles by Anichini, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mortarini, R.
Right arrow Articles by Anichini, A.
[Cancer Research 60, 3559-3568, July 1, 2000]
© 2000 American Association for Cancer Research


Immunology

Peripheral Burst of Tumor-specific Cytotoxic T Lymphocytes and Infiltration of Metastatic Lesions by Memory CD8+ T Cells in Melanoma Patients Receiving Interleukin 121

Roberta Mortarini, Alessandra Borri, Gabrina Tragni, Ilaria Bersani, Claudia Vegetti, Emilio Bajetta, Silvana Pilotti, Vincenzo Cerundolo and Andrea Anichini2

Department of Experimental Oncology, Unit of Human Tumors Immunobiology [R. M., A. B., I. B., C. V., A. A.], and Divisions of Pathology [G. T., S. P.] and of Medical Oncology B [E. B.], Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy, and Institute of Molecular Medicine, Nuffield Department of Clinical Medicine, Oxford, OX3 9DS, United Kingdom [V. C.]

Systemic effects on T-cell-mediated antitumor immunity, on expression of T-cell adhesion/homing receptors, and on the promotion of T-cell infiltration of neoplastic tissue may represent key steps for the efficacy of immunological therapies of cancer. In this study, we investigated whether these processes can be promoted by s.c. administration of low-dose (0.5 µg/kg) recombinant human interleukin-12 (rHuIL-12) to metastatic melanoma patients. A striking burst of HLA-restricted CTL precursors (CTLp) directed to autologous tumor was documented in peripheral blood by a high-efficiency limiting dilution analysis technique within a few days after rHuIL-12 injection. A similar burst in peripheral CTLp frequency was observed even when looking at response to a single tumor-derived peptide, as documented by an increase in Melan-A/Mart-127–35-specific CTLp in two HLA-A*0201+ patients by limiting dilution analysis and by staining peripheral blood lymphocytes (PBLs) with HLA-A*0201-melanoma antigen-A/melanoma antigen recognized by T cells (Melan-A/Mart)-1 tetrameric complexes. The CTLp burst was associated, in PBLs, with enhanced expression of T-cell adhesion/homing receptors CD11a/CD18, CD49d, CD44, and with increased proportion of cutaneous lymphocyte antigen (CLA)-positive T cells. This was matched by a marked increase, in serum, of soluble forms of the endothelial cell adhesion molecules E-selectin, vascular cell adhesion molecules (VCAM)-1 and intercellular adhesion molecules (ICAM)-1. Infiltration of neoplastic tissue by CD8+ T cells with a memory and cytolytic phenotype was found by immunohistochemistry in eight of eight posttreatment metastatic lesions but not in five of five pretreatment metastatic lesions from three patients. Increased tumor necrosis and/or fibrosis were also found in several posttherapy lesions of two of three patients in comparison with pretherapy metastases. These results provide the first evidence that rHuIL-12 can boost the frequency of circulating antitumor CTLp in tumor patients, enhances expression of ligand receptor pairs contributing to the lymphocyte function-associated antigen-1/ICAM-1, very late antigen-4/VCAM-1, and CLA/E-selectin adhesion pathways, and promotes infiltration of neoplastic lesions by CD8+ memory T cells in a clinical setting.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
M. Del Vecchio, E. Bajetta, S. Canova, M. T. Lotze, A. Wesa, G. Parmiani, and A. Anichini
Interleukin-12: Biological Properties and Clinical Application
Clin. Cancer Res., August 15, 2007; 13(16): 4677 - 4685.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. Murugaiyan, R. Agrawal, G. C. Mishra, D. Mitra, and B. Saha
Differential CD40/CD40L Expression Results in Counteracting Antitumor Immune Responses
J. Immunol., February 15, 2007; 178(4): 2047 - 2055.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. Murugaiyan, R. Agrawal, G. C. Mishra, D. Mitra, and B. Saha
Functional Dichotomy in CD40 Reciprocally Regulates Effector T Cell Functions
J. Immunol., November 15, 2006; 177(10): 6642 - 6649.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Petti, A. Molla, C. Vegetti, S. Ferrone, A. Anichini, and M. Sensi
Coexpression of NRASQ61R and BRAFV600E in Human Melanoma Cells Activates Senescence and Increases Susceptibility to Cell-Mediated Cytotoxicity.
Cancer Res., July 1, 2006; 66(13): 6503 - 6511.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. M.L. van Herpen, J. A.W.M. van der Laak, I. J. M. de Vries, J. H. van Krieken, P. C. de Wilde, M. G.J. Balvers, G. J. Adema, and P. H.M. De Mulder
Intratumoral Recombinant Human Interleukin-12 Administration in Head and Neck Squamous Cell Carcinoma Patients Modifies Locoregional Lymph Node Architecture and Induces Natural Killer Cell Infiltration in the Primary Tumor
Clin. Cancer Res., March 1, 2005; 11(5): 1899 - 1909.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
M. Mitsuhashi, J. Liu, S. Cao, X. Shi, and X. Ma
Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas
J. Leukoc. Biol., August 1, 2004; 76(2): 322 - 332.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
X. Shi, S. Cao, M. Mitsuhashi, Z. Xiang, and X. Ma
Genome-Wide Analysis of Molecular Changes in IL-12-Induced Control of Mammary Carcinoma via IFN-{gamma}-Independent Mechanisms
J. Immunol., April 1, 2004; 172(7): 4111 - 4122.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. E. A. Portielje, C. H. J. Lamers, W. H. J. Kruit, A. Sparreboom, R. L. H. Bolhuis, G. Stoter, C. Huber, and J. W. Gratama
Repeated Administrations of Interleukin (IL)-12 Are Associated with Persistently Elevated Plasma Levels of IL-10 and Declining IFN-{gamma}, Tumor Necrosis Factor-{alpha}, IL-6, and IL-8 Responses
Clin. Cancer Res., January 1, 2003; 9(1): 76 - 83.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Wan, L. Lu, J. L. Bramson, S. Baral, Q. Zhu, A. Pilon, and K. Dayball
Dendritic Cell-Derived IL-12 Is Not Required for the Generation of Cytotoxic, IFN-{gamma}-Secreting, CD8+ CTL In Vivo
J. Immunol., November 1, 2001; 167(9): 5027 - 5033.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Salio, D. Shepherd, P. R. Dunbar, M. Palmowski, K. Murphy, L. Wu, and V. Cerundolo
Mature Dendritic Cells Prime Functionally Superior Melan-A-Specific CD8+ Lymphocytes as Compared with Nonprofessional APC
J. Immunol., August 1, 2001; 167(3): 1188 - 1197.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Cifaldi, E. Quaglino, E. Di Carlo, P. Musiani, M. Spadaro, P. L. Lollini, S. Wolf, K. Boggio, G. Forni, and F. Cavallo
A Light, Nontoxic Interleukin 12 Protocol Inhibits HER-2/neu Mammary Carcinogenesis in BALB/c Transgenic Mice with Established Hyperplasia
Cancer Res., April 1, 2001; 61(7): 2809 - 2812.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.